RxDoctor Payments Data

Asif Ali, MD

Cardiovascular Disease · Houston, TXNPI 1881621993

Payments from drug & device makers

$410,524in general payments, 2019–2025

Across 999 payments — averaging $410.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boehringer Ingelheim$143K
  • Lilly USA, LLC$118K
  • Preventric Diagnostics, Inc.$78K
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$51K
  • Abbott$5K
  • Novartis$3K
  • plus $13K from 54 others
$119in research payments, 2019–2025

Across 1 payment — averaging $119.49 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Cleerly, Inc.$119

What the payments were for

  • Consulting fees$81,83320%
  • Speaking & faculty fees$286,70870%
  • Travel & lodging$15,4854%
  • Food & beverage$26,3526%
  • Education$1470%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Boehringer Ingelheim211$143,053
Lilly USA, LLC146$118,123
Preventric Diagnostics, Inc.6$78,083
ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)90$50,898
Abbott74$5,208
Novartis56$2,551
Cleerly, Inc.29$891
Johnson & Johnson41$872
Boston Scientific19$834
Amgen35$822
AstraZeneca14$565
Ablative Solutions, Inc.7$552
Pfizer15$537
Merck25$498
Medtronic(2 entities)11$470
Arbor Pharmaceuticals, Inc.37$417
Actelion Pharmaceuticals US, Inc.20$412
Novo Nordisk11$408
Lexicon Pharmaceuticals, Inc.9$364
E.r. Squibb & Sons, L.L.C.13$346
Bardy Diagnostics, Inc.3$335
Astellas Pharma US Inc11$330
Baxter Healthcare8$320
Esperion Therapeutics, Inc.19$280
Akcea Therapeutics, Inc.7$250
Heartflow, Inc.2$241
Corcept Therapeutics2$234
Abiomed2$231
Lundbeck LLC12$224
Acarix USA Inc.2$218
Philips North America LLC2$182
Endologix LLC1$182
Impulse Dynamics (USA) Inc.2$171
Amarin Pharma, Inc.9$164
Biotronik Inc.2$147
Kiniksa Pharmaceuticals, Ltd.5$121
Sanofi-aventis U.S. LLC7$121
Bard Peripheral Vascular, Inc.1$113
Azurity Pharmaceuticals, Inc.4$79
Idorsia Pharmaceuticals US Inc1$70
Surmodics, Inc.2$50
Scpharmaceuticals Inc.2$49
Kiniksa Pharmaceuticals International, PLC2$47
Veryan Medical Incorporated1$42
Preventice Services, LLC2$40
Gilead2$36
Relievant Medsystems, Inc.1$34
Bolton Medical Inc1$30
Innovation Technologies Inc1$29
Kestra Medical Technology Services, Inc.1$25
Irhythm Technologies, Inc.1$25
Nevro Corp.1$24
GSK1$23
Tactile Systems Technology Inc1$22
Althera Pharmaceuticals LLC2$21
Mayne Pharma Commercial LLC1$21
Agepha Pharma FZ LLC1$18
Myocardial Solutions, Inc.1$15
Cardiva Medical, Inc.1$15
Cashflow Solutions, LLC1$14

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$410,524 in reported general payments places this provider in the 95th percentile of 1,515 cardiovascular disease providers in Texas.

See all cardiovascular disease providers in Texas

Medicare billing

Part B allowed, 2024
$172,142
Medicare patients
244
Services billed
1,475

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban119$125,291
EntrestoSacubitril/Valsartan71$59,064
JardianceEmpagliflozin63$54,045
XareltoRivaroxaban50$52,700
EdarbiAzilsartan Medoxomil55$28,060
Repatha SureclickEvolocumab20$16,721
CorlanorIvabradine Hcl15$11,980
EdarbyclorAzilsartan Med/Chlorthalidone23$9,720
Olmesartan Medoxomil309$3,741
Droxidopa16$3,693
LivaloPitavastatin Calcium11$3,413
Metoprolol Succinate254$2,836
Ezetimibe106$2,456
Isosorbide Dinit-HydralazineIsosorbide Dinit/Hydralazine19$2,303
Amlodipine Besylate294$1,896

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$537$125,291119 claims
NovartisEntresto$2,551$59,06471 claims
Boehringer IngelheimJardiance$143,053$54,04563 claims
Johnson & JohnsonXarelto$872$52,70050 claims
Arbor Pharmaceuticals, Inc.Edarbi, Edarbyclor$417$37,78078 claims
AmgenCorlanor$822$11,98015 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,515 cardiovascular disease providers in Texas.

Other cardiovascular disease in Houston

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →